BioMedNewsBreaks

FridayMay 15, 2026 11:53 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a NetworkNewsAudio audio press release focused on emerging opportunities in central nervous system drug delivery, highlighting the challenges posed by the blood-brain barrier and the company’s efforts to advance technologies designed to overcome those limitations. The editorial also noted Oncotelic’s recent strategic monetization agreement with Lunai Bioworks involving its N2B delivery system, supporting initiatives in biodefense and Alzheimer’s disease treatment. To view the full press release, visit https://ibn.fm/ySesO About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic…

Continue Reading

FridayMay 15, 2026 10:30 am

BioMedNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. The editorial noted GEP-44’s triple agonist mechanism targeting GLP-1 and peptide YY receptors, with preclinical data indicating potential benefits in appetite suppression, weight reduction and glycemic control with improved tolerability. To view the full press release, visit https://ibn.fm/wsiDy About SureNano Science Ltd. SureNano Science Ltd. (CSE:…

Continue Reading

FridayMay 15, 2026 10:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports First-Quarter Results, Highlights Progress Across Biotech Platform

Oncotelic Therapeutics (OTCQB: OTLC) reported first-quarter 2026 financial results and a corporate update highlighting continued advancement across its oncology, AI-enabled drug development and advanced drug delivery initiatives, including progress within its Sapu Nano joint venture and nose-to-brain CNS delivery platform. The company also said it maintained the previously established approximately $388 million fair value of its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while continuing to pursue capital-efficient growth across its diversified biotechnology platform. To view the full press release, visit https://ibn.fm/DTVsF About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the…

Continue Reading

ThursdayMay 14, 2026 11:36 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation 

Oncotelic Therapeutics (OTCQB: OTLC) announced its featured placement in a BioMedWire editorial focused on emerging CNS drug delivery technologies addressing challenges in Alzheimer’s disease and biodefense research. The editorial highlights the company’s proprietary intranasal nose-to-brain delivery platform, designed to bypass the blood-brain barrier and enable direct therapeutic delivery to the central nervous system, reflecting growing interest in advanced drug delivery approaches for neurological treatment. To view the full press release, visit https://ibn.fm/aSsCf About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage…

Continue Reading

ThursdayMay 14, 2026 11:27 am

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its featured placement in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the treatment of obesity, type 2 diabetes and related metabolic conditions. To view the full press release, visit https://ibn.fm/9zCgz About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing…

Continue Reading

ThursdayMay 14, 2026 10:00 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on Real-Time Intoxication Detection Technologies

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced its featured placement in an editorial published by BioMedWire, highlighting emerging opportunities in real-time intoxication detection technologies. The editorial spotlights MindBio’s AI-driven voice analysis platform, which is being developed to detect impairment from brief speech recordings across a range of substances, addressing growing demand for faster, noninvasive and scalable intoxication detection solutions across healthcare, workplace safety and public health applications. To view the full press release, visit https://ibn.fm/1WCqA About MindBio Therapeutics Corp. MindBio is a…

Continue Reading

ThursdayMay 14, 2026 9:50 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs. To view the full press release, visit https://ibn.fm/HP5Xy About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive…

Continue Reading

ThursdayMay 14, 2026 9:40 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives 2026 Healthcare Innovation Award for Drug Resistance Research

Kairos Pharma (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches. To view the full press release, visit https://ibn.fm/WuBOf About Kairos Pharma, Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune…

Continue Reading

ThursdayMay 14, 2026 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results

HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives. To view the full press release, visit https://ibn.fm/guMCF About HeartBeam, Inc. HeartBeam,…

Continue Reading

WednesdayMay 13, 2026 11:31 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces First Patient Dosed in Phase 1b Trial of Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), alongside Sapu Nano, announced that the first patient has been dosed in the Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle(TM) formulation of everolimus for patients with advanced mTOR-sensitive solid tumors. The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity across patient cohorts including HR-positive/HER2-negative breast cancer and multiple additional tumor types, with Sapu003 developed as a weekly IV formulation intended to address limitations associated with oral everolimus delivery, including variable absorption and dose-limiting toxicity. To view the full press release, visit https://ibn.fm/JuGIs About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development…

Continue Reading